BR112018008496A2 - tratamento de esteatose hepática relacionada com oligo ovulação - Google Patents

tratamento de esteatose hepática relacionada com oligo ovulação

Info

Publication number
BR112018008496A2
BR112018008496A2 BR112018008496A BR112018008496A BR112018008496A2 BR 112018008496 A2 BR112018008496 A2 BR 112018008496A2 BR 112018008496 A BR112018008496 A BR 112018008496A BR 112018008496 A BR112018008496 A BR 112018008496A BR 112018008496 A2 BR112018008496 A2 BR 112018008496A2
Authority
BR
Brazil
Prior art keywords
treatment
ovulation
oligo
liver steatosis
related liver
Prior art date
Application number
BR112018008496A
Other languages
English (en)
Inventor
Ibáñez Lourdes
De Zegher Francis
Original Assignee
Katholieke Universiteit Leuven
Hospital Sant Joan De Deu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, Hospital Sant Joan De Deu filed Critical Katholieke Universiteit Leuven
Publication of BR112018008496A2 publication Critical patent/BR112018008496A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a um processo e composição para uso no tratamento de uma condição que se beneficia da redução de gordura hepática e/ou gordura visceral, tal como síndrome de ovário policístico em meninas adolescentes ou mulheres de idade de gravidez e parto, envolvendo o uso de spironolactona, pioglitazona e metformina.
BR112018008496A 2015-10-27 2016-10-27 tratamento de esteatose hepática relacionada com oligo ovulação BR112018008496A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518979.8A GB201518979D0 (en) 2015-10-27 2015-10-27 Treatment of hepatic steatosis related oligo-ovulation
PCT/EP2016/075953 WO2017072243A1 (en) 2015-10-27 2016-10-27 Treatment of hepatic steatosis related oligo-ovulation

Publications (1)

Publication Number Publication Date
BR112018008496A2 true BR112018008496A2 (pt) 2018-10-23

Family

ID=55130283

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008496A BR112018008496A2 (pt) 2015-10-27 2016-10-27 tratamento de esteatose hepática relacionada com oligo ovulação

Country Status (24)

Country Link
US (2) US20190060328A1 (pt)
EP (2) EP3892281A3 (pt)
JP (2) JP6999903B2 (pt)
KR (1) KR102608158B1 (pt)
CN (2) CN108778285A (pt)
AR (1) AR106505A1 (pt)
AU (1) AU2016344737C1 (pt)
BR (1) BR112018008496A2 (pt)
CA (1) CA3003076C (pt)
DK (1) DK3368044T3 (pt)
ES (1) ES2883282T3 (pt)
GB (1) GB201518979D0 (pt)
HU (1) HUE055778T2 (pt)
IL (1) IL258876B (pt)
LT (1) LT3368044T (pt)
MA (2) MA43106B1 (pt)
MX (2) MX2018005252A (pt)
PL (1) PL3368044T3 (pt)
RS (1) RS62764B1 (pt)
RU (1) RU2745606C2 (pt)
SI (1) SI3368044T1 (pt)
TW (1) TWI791420B (pt)
UY (1) UY36967A (pt)
WO (1) WO2017072243A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091509A1 (ru) 2017-12-19 2020-09-22 Акуос, Инк. Aav-опосредованная доставка терапевтических антител во внутреннее ухо
EP3829546A1 (en) * 2018-08-02 2021-06-09 Hospital Sant Joan de Deu Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome
EP3842803A1 (en) * 2019-12-23 2021-06-30 Katholieke Universiteit Leuven Cxcl14 in polycystic ovary syndrome
CA3183171A1 (en) 2020-05-13 2021-11-18 Akouos, Inc. Compositions and methods for treating slc26a4-associated hearing loss
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
PE20240012A1 (es) 2020-12-29 2024-01-04 Akouos Inc Composiciones y metodos para tratar la perdida de audicion y/o la perdida de vision asociada a clrn1
TW202342525A (zh) 2022-02-02 2023-11-01 美商阿科奧斯公司 用於治療前庭神經鞘瘤相關症狀之抗ｖｅｇｆ抗體構築體及相關方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
WO2001062237A2 (en) * 2000-02-23 2001-08-30 Orentreich Foundation For The Advancement Of Science, Inc. Compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
GB0106565D0 (en) * 2001-03-16 2001-05-09 Leuven K U Res & Dev Growth hormone treatment
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
AU2003256988A1 (en) * 2002-12-11 2004-06-30 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
GB0702537D0 (en) * 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US10474539B1 (en) * 2015-12-18 2019-11-12 EMC IP Holding Company LLC Browsing federated backups
EP3829546A1 (en) * 2018-08-02 2021-06-09 Hospital Sant Joan de Deu Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome

Also Published As

Publication number Publication date
CN117379440A (zh) 2024-01-12
EP3368044A1 (en) 2018-09-05
EP3368044B1 (en) 2021-06-09
EP3892281A2 (en) 2021-10-13
AU2016344737C1 (en) 2021-10-07
US20240000804A1 (en) 2024-01-04
AU2016344737B2 (en) 2021-07-08
RU2745606C2 (ru) 2021-03-29
GB201518979D0 (en) 2015-12-09
SI3368044T1 (sl) 2022-05-31
RU2018119146A3 (pt) 2020-02-25
UY36967A (es) 2017-05-31
AR106505A1 (es) 2018-01-24
AU2016344737A1 (en) 2018-05-17
EP3892281A3 (en) 2021-11-10
JP6999903B2 (ja) 2022-02-04
JP2019501113A (ja) 2019-01-17
MA43106B1 (fr) 2021-09-30
LT3368044T (lt) 2021-10-25
MX2018005252A (es) 2018-09-18
MA54412A (fr) 2021-11-10
WO2017072243A9 (en) 2018-07-26
RS62764B1 (sr) 2022-01-31
TWI791420B (zh) 2023-02-11
WO2017072243A8 (en) 2018-03-22
PL3368044T3 (pl) 2021-12-20
MX2021007976A (es) 2021-08-16
IL258876B (en) 2022-03-01
WO2017072243A1 (en) 2017-05-04
CA3003076C (en) 2023-12-05
CN108778285A (zh) 2018-11-09
RU2018119146A (ru) 2019-11-28
AU2016344737A9 (en) 2018-08-09
IL258876A (en) 2018-06-28
JP2022009374A (ja) 2022-01-14
KR102608158B1 (ko) 2023-11-29
CA3003076A1 (en) 2017-05-04
DK3368044T3 (da) 2021-09-13
MA43106A (fr) 2021-05-05
HUE055778T2 (hu) 2021-12-28
TW201720432A (zh) 2017-06-16
ES2883282T3 (es) 2021-12-07
US20190060328A1 (en) 2019-02-28
KR20180098234A (ko) 2018-09-03

Similar Documents

Publication Publication Date Title
BR112018008496A2 (pt) tratamento de esteatose hepática relacionada com oligo ovulação
BR112018005194A2 (pt) processo de composto antifúngico
CL2016000839A1 (es) Composiciones para modular la expresión de c9orf72.
UY36357A (es) Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa))
BR112017020993A2 (pt) compostos, processo para a síntese de compostos, composição, uso de um composto da fórmula i, método para combater fungos fitopatogênicos, e, semente.
BR112018072196A2 (pt) amplificação de incompatibilidade otimizada multiplexadas (moma) - número do alvo
BR112017012434A2 (pt) composições de canabinóide microencapsuladas
BR112014019045A8 (pt) Composições pesticidas e processos relacionados às mesmas
BR112018010381A2 (pt) composições para tratamento de cabelo, condicionadora de cabelo e para alteração da cor do cabelo, sistema para tratamento de cabelo, métodos para tratamento de cabelo e para alteração da cor do cabelo, e, kit de multicompartimentos.
BR112018003864A2 (pt) método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido
BR112016021282A8 (pt) processos para a preparação de compostos antifúngicos e os referidos compostos
EP3280262A4 (en) Synergistic benzoxaborole-containing anti-fungicidal composition
BR112017010669A2 (pt) composição, método para reduzir o número de patógenos sobre uma superfície e método para reduzir o número de patógenos em um volume de um produto alimentício
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112016009482B8 (pt) Composição de revestimento, uso de uma composição de revestimento, processo para preparação de uma composição de revestimento e método para cura de uma composição de revestimento
BR112018010140A2 (pt) compostos de fórmula, composição, utilização de um composto de fórmula, método para o combate de fungos fitopatogênicos e semente
BR112017019352A2 (pt) composições tópicas comprimidas a corticosteróide aplicações relacionadas
BR112016023729A2 (pt) espelho de veículo e método para a fabricação de tal espelho
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
UY37519A (es) Fenilamidinas y su uso como fungicidas
BR112018010316A2 (pt) compostos de fórmula, composição, utilização de um composto de fórmula, método para o combate de fungos fitopatogênicos e semente
BR112017018172B8 (pt) Método para romper um biofilme através de composições compreendendo combinações de ácidos orgânicos
MX2017003550A (es) Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos.
BR112017014272A2 (pt) método para determinar íons de ferro e kit
BR112018012365A2 (pt) copolímero de etileno e de butadieno de miicroestrutura homogênea

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]